We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02176317
Recruitment Status : Completed
First Posted : June 27, 2014
Last Update Posted : December 3, 2019
The Marcus Foundation
PerkinElmer, Inc.
Information provided by (Responsible Party):
Joanne Kurtzberg, MD, Duke University

Brief Summary:
This study is a prospective phase 1 single-center trial designed to determine the safety of a single intravenous infusion of autologous umbilical cord blood in children with Autism Spectrum Disorder (ASD) and assess the feasibility of various outcome measures to determine which measure(s) can be used as primary and secondary endpoints for a future randomized phase 2 clinical trial. All subjects will receive infusion of cord blood cells at baseline with follow up assessments at 6 and 12 months.

Condition or disease Intervention/treatment Phase
Autism Spectrum Disorder Biological: Autologous Umbilical Cord Blood Phase 1

Detailed Description:
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder with early onset in life. Currently, available treatments for patients with ASD are supportive, but not curative. Umbilical cord blood (UCB) has been shown to lessen the clinical and radiographic impact of hypoxic brain injury and stroke in animal models and in infants with hypoxic ischemic encephalopathy. UCB also engrafts and differentiates in the brain, facilitating neural cell repair in animal models and human patients with inborn errors of metabolism undergoing allogeneic, unrelated donor UCB transplantation. Infusion of autologous UCB does not require immunosuppression and has been shown to be safe in young children with brain injuries such as cerebral palsy and stroke. In this study, the investigators hypothesize that infusion of a patient's own umbilical cord blood cells (UCB) can offer neural protection/repair in the brain and reduction of inflammation associated with this disorder.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)
Study Start Date : June 2014
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Autologous Umbilical Cord Blood (UCB)
All participants will receive a single intravenous (into the vein) infusion of autologous umbilical cord blood cells.
Biological: Autologous Umbilical Cord Blood
All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes

Primary Outcome Measures :
  1. Number of participants with non-serious and serious adverse events. [ Time Frame: up to 12 months ]

Secondary Outcome Measures :
  1. The primary efficacy measure will be change in the Vineland Adaptive Behavior Scale- II [ Time Frame: up to 12 months ]

Other Outcome Measures:
  1. Change in Pervasive Developmental Disorder- Behavior Inventory [ Time Frame: up to 12 months ]
  2. Change in Repetitive Behavior Scal [ Time Frame: up to 12 months ]
  3. Change in Sensory Experience Questionnaire [ Time Frame: up to 12 months ]
  4. Change in Behavior Assessment of Children [ Time Frame: up to 12 months ]
  5. Change in Autism Diagnostic Observation Scale [ Time Frame: up to 12 months ]
  6. Change in Clinical Global Impression- Severity and Improvement Scales [ Time Frame: up to 12 months ]
  7. Change in Stanford Binet Intelligence Scale or other standardized IQ test [ Time Frame: up to 12 months ]
  8. Change in frequency of child vocalization/ conversational turns [ Time Frame: up to 12 months ]
  9. Change in Expressive One-Word Picture Vocabulary Test [ Time Frame: up to 12 months ]
  10. Change in Preschool Age Psychiatric Assessment [ Time Frame: up to 12 months ]
  11. Change in Aberrant Behavior Checklist [ Time Frame: up to 12 months ]
  12. Prevalent and incident of GI symptoms [ Time Frame: up to 12 months ]
  13. Change in Parenting Stress Index [ Time Frame: up to 12 months ]
  14. Change in attention to social stimuli assessed via eye-tracking and electroencephalography (EEG) [ Time Frame: up to 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   24 Months to 72 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 24 months to ≤72months at the time of visit 1
  2. Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using all three of the following measures:

    • Autism Diagnostic Observation Schedule - Toddler or Generic (ADOS)
    • Autism Diagnostic Interview-Revised (ADI-R)
    • DSM-5 checklist
  3. IQ ≥ 35 on Stanford Binet Intelligence Scale or similar standardized test
  4. Autologous umbilical cord blood available from a cord blood bank with a minimum total nucleated cell dose of ≥ 1 x 107 cells/kilogram of subject weight that meets acceptance criteria outlined in section 6.0 with confirmed HLA matching
  5. Stable on current medications for at least 2 months prior to infusion of cord blood
  6. Ability to travel to Duke University three times (0, 6, 12 mo.), parent/guardian able to participate in electronic communication tracking two times in the study and interim phone surveys every 3 months
  7. Parental consent
  8. Subject and parent/guardian must be English speaking

Exclusion Criteria:

  1. Unwilling to commit to follow up for a year
  2. History of prior cell therapy
  3. Use of IVIG or other anti-inflammatory medications with the exception of NSAIDs
  4. Medical records indicate that child has genetic or other syndromes such as fragile X, neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cerebral palsy, cystic fibrosis, muscular dystrophy, Crohn's disease, or rheumatoid disease
  5. Co-morbid condition that would influence child's performance on assessments.
  6. Central Nervous System (CNS) infection
  7. History of unstable epilepsy or uncontrolled seizure disorder, infantile spasms, Lennox Gastaut syndrome, Dravet syndrome
  8. Known pathogenic copy number variation (CNV) (e.g. 16p11.2, 15q13.2, 2q13.3)
  9. Significant sensory (i.e., deafness, blind) or motor impairment (CP) (if using Language Environment Analysis (LENA), no uncorrected hearing impairment)
  10. Presence of obvious physical dysmorphology
  11. Review of medical records indicates ASD diagnosis not likely or other serious complicating genetic or medical condition present
  12. Impaired renal or liver function as determined by serum creatinine >1.5mg/dL and/or total bilirubin>1.3mg/dL
  13. Clinically significant abnormalities in Complete Blood Count (CBC): Hemoglobin < 10.0 g/dL, White Blood Count (WBC) < 3.8 x 10e9, Platelets < 150x 10e9.
  14. Known metabolic disorder, mitochondrial dysfunction
  15. Uncontrolled infection, presence of or infection with HIV
  16. Active malignancy
  17. Macroencephaly or microencephaly ( >2 standard deviations in the relevant direction between head circumference and height)
  18. Change in current stable use of psychoactive medications; as per parent report.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02176317

Layout table for location information
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27705
Sponsors and Collaborators
Duke University
The Marcus Foundation
PerkinElmer, Inc.
Layout table for investigator information
Principal Investigator: Joanne Kurtzberg, MD Duke University
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Joanne Kurtzberg, MD, Professor of Pediatrics, Duke University
ClinicalTrials.gov Identifier: NCT02176317    
Other Study ID Numbers: Pro00052449
First Posted: June 27, 2014    Key Record Dates
Last Update Posted: December 3, 2019
Last Verified: December 2019
Keywords provided by Joanne Kurtzberg, MD, Duke University:
Autism Spectrum Disorder
Umbilical cord blood
Autologous cord blood
cord blood
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Pathologic Processes
Neurodevelopmental Disorders
Mental Disorders